155 related articles for article (PubMed ID: 18228526)
1. Fluorescent labeled anti-EGFR antibody for identification of regional and distant metastasis in a preclinical xenograft model.
Gleysteen JP; Newman JR; Chhieng D; Frost A; Zinn KR; Rosenthal EL
Head Neck; 2008 Jun; 30(6):782-9. PubMed ID: 18228526
[TBL] [Abstract][Full Text] [Related]
2. Use of fluorescent labeled anti-epidermal growth factor receptor antibody to image head and neck squamous cell carcinoma xenografts.
Rosenthal EL; Kulbersh BD; King T; Chaudhuri TR; Zinn KR
Mol Cancer Ther; 2007 Apr; 6(4):1230-8. PubMed ID: 17431103
[TBL] [Abstract][Full Text] [Related]
3. Optical imaging predicts tumor response to anti-EGFR therapy.
Helman EE; Newman JR; Dean NR; Zhang W; Zinn KR; Rosenthal EL
Cancer Biol Ther; 2010 Jul; 10(2):166-71. PubMed ID: 20505368
[TBL] [Abstract][Full Text] [Related]
4. In vivo detection of head and neck cancer orthotopic xenografts by immunofluorescence.
Rosenthal EL; Kulbersh BD; Duncan RD; Zhang W; Magnuson JS; Carroll WR; Zinn K
Laryngoscope; 2006 Sep; 116(9):1636-41. PubMed ID: 16954995
[TBL] [Abstract][Full Text] [Related]
5. Preclinical comparison of near-infrared-labeled cetuximab and panitumumab for optical imaging of head and neck squamous cell carcinoma.
Day KE; Sweeny L; Kulbersh B; Zinn KR; Rosenthal EL
Mol Imaging Biol; 2013 Dec; 15(6):722-9. PubMed ID: 23715932
[TBL] [Abstract][Full Text] [Related]
6. Intraoperative fluorescence delineation of head and neck cancer with a fluorescent anti-epidermal growth factor receptor nanobody.
van Driel PB; van der Vorst JR; Verbeek FP; Oliveira S; Snoeks TJ; Keereweer S; Chan B; Boonstra MC; Frangioni JV; van Bergen en Henegouwen PM; Vahrmeijer AL; Lowik CW
Int J Cancer; 2014 Jun; 134(11):2663-73. PubMed ID: 24222574
[TBL] [Abstract][Full Text] [Related]
7. Use of panitumumab-IRDye800 to image microscopic head and neck cancer in an orthotopic surgical model.
Heath CH; Deep NL; Sweeny L; Zinn KR; Rosenthal EL
Ann Surg Oncol; 2012 Nov; 19(12):3879-87. PubMed ID: 22669455
[TBL] [Abstract][Full Text] [Related]
8. The effect of combination anti-endothelial growth factor receptor and anti-vascular endothelial growth factor receptor 2 targeted therapy on lymph node metastasis: a study in an orthotopic nude mouse model of squamous cell carcinoma of the oral tongue.
Sano D; Choi S; Milas ZL; Zhou G; Galer CE; Su YW; Gule M; Zhao M; Zhu Z; Myers JN
Arch Otolaryngol Head Neck Surg; 2009 Apr; 135(4):411-20. PubMed ID: 19380367
[TBL] [Abstract][Full Text] [Related]
9. Sensitivity and specificity of fluorescent immunoguided neoplasm detection in head and neck cancer xenografts.
Kulbersh BD; Duncan RD; Magnuson JS; Skipper JB; Zinn K; Rosenthal EL
Arch Otolaryngol Head Neck Surg; 2007 May; 133(5):511-5. PubMed ID: 17520766
[TBL] [Abstract][Full Text] [Related]
10. The role of cetuximab in the treatment of squamous cell cancer of the head and neck.
Burtness B
Expert Opin Biol Ther; 2005 Aug; 5(8):1085-93. PubMed ID: 16050785
[TBL] [Abstract][Full Text] [Related]
11. Stereomicroscopic fluorescence imaging of head and neck cancer xenografts targeting CD147.
Newman JR; Gleysteen JP; Barañano CF; Bremser JR; Zhang W; Zinn KR; Rosenthal EL
Cancer Biol Ther; 2008 Jul; 7(7):1063-70. PubMed ID: 18431087
[TBL] [Abstract][Full Text] [Related]
12. Role of near-infrared fluorescence imaging in the resection of metastatic lymph nodes in an optimized orthotopic animal model of HNSCC.
Atallah I; Milet C; Quatre R; Henry M; Reyt E; Coll JL; Hurbin A; Righini CA
Eur Ann Otorhinolaryngol Head Neck Dis; 2015 Dec; 132(6):337-42. PubMed ID: 26409829
[TBL] [Abstract][Full Text] [Related]
13. 111In-cetuximab-F(ab')2 SPECT imaging for quantification of accessible epidermal growth factor receptors (EGFR) in HNSCC xenografts.
van Dijk LK; Hoeben BA; Stegeman H; Kaanders JH; Franssen GM; Boerman OC; Bussink J
Radiother Oncol; 2013 Sep; 108(3):484-8. PubMed ID: 23932156
[TBL] [Abstract][Full Text] [Related]
14. Radiolabeled cetuximab: dose optimization for epidermal growth factor receptor imaging in a head-and-neck squamous cell carcinoma model.
Hoeben BA; Molkenboer-Kuenen JD; Oyen WJ; Peeters WJ; Kaanders JH; Bussink J; Boerman OC
Int J Cancer; 2011 Aug; 129(4):870-8. PubMed ID: 20957635
[TBL] [Abstract][Full Text] [Related]
15. Characterization of ABT-806, a Humanized Tumor-Specific Anti-EGFR Monoclonal Antibody.
Reilly EB; Phillips AC; Buchanan FG; Kingsbury G; Zhang Y; Meulbroek JA; Cole TB; DeVries PJ; Falls HD; Beam C; Gu J; Digiammarino EL; Palma JP; Donawho CK; Goodwin NC; Scott AM
Mol Cancer Ther; 2015 May; 14(5):1141-51. PubMed ID: 25731184
[TBL] [Abstract][Full Text] [Related]
16. Mapping Sentinel Lymph Node Metastasis by Dual-probe Optical Imaging.
Yang X; Wang Z; Zhang F; Zhu G; Song J; Teng GJ; Niu G; Chen X
Theranostics; 2017; 7(1):153-163. PubMed ID: 28042324
[No Abstract] [Full Text] [Related]
17. EGFR inhibitors for the treatment of squamous cell carcinoma of the head and neck.
Mehra R; Cohen RB; Harari PM
Curr Oncol Rep; 2008 Mar; 10(2):176-84. PubMed ID: 18377832
[TBL] [Abstract][Full Text] [Related]
18. Targeting ErbB-1 and ErbB-4 in irradiated head and neck cancer: results of in vitro and in vivo studies.
Barnea I; Haif S; Keshet R; Karaush V; Lev-Ari S; Khafif A; Shtabsky A; Yarden Y; Vexler A; Ben Yosef R
Head Neck; 2013 Mar; 35(3):399-407. PubMed ID: 22367849
[TBL] [Abstract][Full Text] [Related]
19. Assessment of indocyanine green-labeled cetuximab to detect xenografted head and neck cancer cell lines.
Withrow KP; Gleysteen JP; Safavy A; Skipper J; Desmond RA; Zinn K; Rosenthal EL
Otolaryngol Head Neck Surg; 2007 Nov; 137(5):729-34. PubMed ID: 17967636
[TBL] [Abstract][Full Text] [Related]
20. Cetuximab: from bench to bedside.
Vincenzi B; Zoccoli A; Pantano F; Venditti O; Galluzzo S
Curr Cancer Drug Targets; 2010 Feb; 10(1):80-95. PubMed ID: 20088790
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
